Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_assertion type Assertion NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_head.
- NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_assertion description "[The most prevalent biomarkers in pulmonary adenocarcinoma were KRAS mutations (29%), loss of PTEN expression (18%), EGFR mutations (9%), HER2 amplification (5%) and BRAF mutations (3%), while the prevalence of ALK translocations and PIK3CA mutations was extremely low.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_provenance.
- NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_assertion evidence source_evidence_literature NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_provenance.
- NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_assertion SIO_000772 23876834 NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_provenance.
- NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_assertion wasDerivedFrom befree-2016 NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_provenance.
- NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_assertion wasGeneratedBy ECO_0000203 NP1095870.RALeoZ-8wXjRO7_999PPYs7rQHAssUkebn_fuaF4ZdAlY130_provenance.